Becton Dickinson 

$238.22
510
+$0.86+0.36% Friday 20:00

統計

當日最高
238.91
當日最低
236.58
52週最高
269.52
52週最低
218.75
成交量
652,180
平均成交量
1,387,118
市值
70.07B
市盈率
48.58
股息收益率
1.6%
股息
3.8

即將到來

股息

1.6%股息收益率
10年增長
5.45%
5年增長率
4.16%
3年增長率
4.19%
1年增長率
3.26%

收益

7Nov預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
2.4
2.85
3.31
3.76
預期每股收益
3.764367
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 BDX 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

283.5$平均價格目標
最高估價為 $312。
來自過去 6 個月內的 6 個評級。這不是投資建議。
買入
100%
持有
0%
賣出
0%

關於

Health Technology
Medical Specialties
Manufacturing
Surgical and Medical Instrument Manufacturing
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Show more...
首席執行官
Thomas Polen
員工
70000
國家
US
ISIN
US0758871091

上市公司